4DMT Reports FDA Clearance Of IND Application For 4D-175 Genetic Medicine For Treatment Of Geographic Atrophy
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics (FDMT) announced that the FDA has cleared its IND application for 4D-175, a genetic medicine for treating geographic atrophy. The treatment uses a proprietary AAV vector and a codon-optimized transgene. Phase 1 clinical trial enrollment is expected to begin in H2 2024.
June 24, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
4D Molecular Therapeutics (FDMT) has received FDA clearance for its IND application for 4D-175, a genetic medicine aimed at treating geographic atrophy. This regulatory milestone is significant as it paves the way for Phase 1 clinical trials, expected to begin in H2 2024.
The FDA clearance is a critical regulatory milestone for FDMT, allowing the company to proceed with clinical trials for 4D-175. This development is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100